The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Firm yields push dollar to a 4-month high

Wed, 25th Apr 2018 09:03

* Dollar rises 0.3 percent on U.S. yields

* Investors focused on Thursday's ECB meeting

* Graphic: World FX rates in 2018 http://tmsnrt.rs/2egbfVh

By Tom Finn

LONDON, April 25 (Reuters) - The dollar hit a four-monthhigh on Wednesday after a rise in benchmark U.S. Treasury yieldsabove 3 percent rattled some currency bears while a mixedpicture from business surveys failed to help the euro before aEuropean Central Bank meeting.

Asian shares fell on Wednesday after a sharp sell-off inU.S. markets and warnings from U.S. companies of higher costsdrove fears that a boom in corporate earnings may be near itspeak when concerns of fiscal stimulus in a late U.S. economiccycle have pushed bond yields higher.

"With rising bond yields spoiling the fun and disappointmentaround the U.S. tech sector putting a dampener on sentiment,hopes are pinned on earnings delivering," said Societe Generalemacro strategist Kit Juckes.

The dollar index against a basket of six major currenciesrose 0.4 percent to 91.093. It had climbed overnight to91.076, highest since Jan. 12, before a slide in Wall Streetstocks tempered investor risk appetite.

Against the yen, the dollar neared a two-month high of109.20 yen hit in the previous session. It was a notchbelow that at 109.18 yen, up 0.3 percent on the day.

The greenback had risen without pause through much of thepast week as U.S.-China trade conflict fears receded and allowedthe market to turn its attention back to dollar-supportivefundamentals, notably the surge by U.S. yields.

The dollar squeeze has been most severe against thosecurrencies heavily backed by speculative investors including theBritish pound, New Zealand dollar and Mexican peso.

Investors are focused on the euro-dollar exchange rate whichhas remain stuck in its recent range.

Analysts say the market needs clarity about the speed of theEuropean Central Bank's monetary tightening cycle before theeuro, which rallied at the start of this year before running outof steam in the last two months, breaks higher.

The ECB holds its monetary policy meeting on Thursday.

The euro stormed into 2018 in rally mode as traders bet thatsynchronized global growth would force the ECB to acceleratemonetary policy normalization.

But the ECB's reluctance so far to signal any shift leavesthe "euro's gains against the dollar vulnerable to setbacks",said Commerzbank analyst Thu Lan Nguyen in a note.

Nguyen said that the euro-dollar exchange rate continues tobe dominated mainly by moves in the US dollar that is nowbeginning to benefit from higher US interest rates.

This week the gap between U.S. and German 10-year governmentbond yields has hit its widest in 29 years and the U.S.-Japanese10-year yield spread reached its broadest in nearly11 years.

The treasury yield extended its overnight rise and touchedthe four-year peak of 3.009 percent, reflecting the durabilityof the U.S. economic expansion. Accelerating inflation andconcerns about increasing debt supply have also driven yieldshigher.

The pound was down 0.2 percent at $1.3947. Itplumbed a one-month low of $1.3919 on Tuesday before rebounding0.3 percent, on news about a possible takeover of Britishpharmaceutical company Shire Plc by Japanese drugmakerTakeda Pharmaceutical Co.

The Australian dollar shed 0.4 percent to $0.7569as it dropped into a four-month trough.

The New Zealand dollar extended losses and dipped to $0.7102NZD=D4, its weakest since Jan. 4.

The Canadian dollar performed a little better on headlinesciting Canadian Foreign Minister Chrystia Freeland that "goodprogress" was being made on NAFTA negotiations.(Editing by Keith Weir)

More News
6 Sep 2019 07:54

UPDATE 1-Sumitomo Dainippon Pharma investing $3 bln in Swiss Roivant in overseas push

* Dainippon to buy 10% stake in Roivant and interests in 5 units * Schizophrenia treatment Latuda to lose US exclusivity in 2023 * Japan pharma firms grapple with declining Dainippon

Read more
14 Aug 2019 06:45

UPDATE 1-Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt

FRANKFURT, Aug 14 (Reuters) - German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development we

Read more
17 Jul 2019 17:55

Takeda kicks off sale of Western European drugs - sources

By Arno Schuetze and Pamela Barbaglia FRANKFURT/LONDON, July 17 (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in

Read more
16 May 2019 18:35

Japan's Takeda expects binding offers for Latam business by end of May -sources

By Tatiana Bautzer SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources of a

Read more
15 May 2019 08:05

Nikkei snaps 7-day losing streak helped by China's stimulus hopes

* Gains may be short-lived - analyst * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi Estate jumps on share buyback, governance reform By Hideyuki Sano and Ayai

Read more
15 May 2019 04:04

Nikkei hobbled by trade worries, disappointing earnings

* Nikkei down slightly after 7 losing sessions * Uncertainties over U.S.-China standoff keep investors on edge * Takeda Pharma, Nissan sink after earnings shock * Mitsubishi -

Read more
14 May 2019 07:56

UPDATE 1-Japan's Takeda forecasts 193 bln yen annual operating loss on Shire deal

* 193 bln Y op loss forecast this yr vs 227.5 bln profit view of analysts * Shire acquisition made Takeda one of the world's most indebted drugmakers (Adds details of results, May 14 -

Read more
14 May 2019 07:39

Japan's Takeda expects annual loss on Shire deal

TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar an a

Read more
9 May 2019 00:38

UPDATE 1-Novartis buys Takeda's dry eye drug for $3.4 bln

May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone of

Read more
1 Feb 2019 06:07

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple

Read more
22 Jan 2019 02:46

Nikkei dips as global growth concerns sap risk appetite

* IMF cuts global growth forecasts * Companies with big China exposure fall * Totech soars after raising earnings forecast By Ayai Tomisawa TOKYO, Jan 22 (Reuters) - in

Read more
8 Jan 2019 13:54

MARKET ANALYSIS: Optimism About Trade Talks May Generate Continued Buying Interest

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Tuesday, with stocks likely to extend the strong upward move seen over the two previous about trade the

Read more
8 Jan 2019 08:58

Asian Shares Mixed Despite US-China Trade Deal Optimism

CANBERA (Alliance News) - Asian stocks ended mixed on Tuesday despite optimism over US-China trade talks as US officials held a second day of trade talks with Chinese counterparts in second day of

Read more
8 Jan 2019 07:39

Takeda takes control of Shire

(Sharecast News) - Takeda Pharmaceutical has taken full control of Shire after the legal particulars of its cash and share offer were completed.

Read more
7 Jan 2019 04:29

Takeda unlikely to sell OTC drug business -CEO

(Adds quote, other details) TOKYO, Jan 7 (Reuters) - Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.